Magnolia officinalis reverses alcoholic fatty liver by inhibiting the maturation of sterol regulatory element-binding protein-1c

Journal of Pharmacological Sciences

Volumn 109, Issue 4, 2009, Pages 486-495

  Yin, Hu Quan ^a   Je, Young Tae ^a   Kim, Young Chul ^a   Shin, Young Kee ^a   Sung, SangHyun ^a   Lee, KiYong ^a   Jeong, Gil Saeng ^b   Kim, Youn Chul ^b   Lee, Byung Hoon ^a  

^a Seoul National University   (South Korea)

^b Wonkwang University   (South Korea)

Author keywords

Alcoholic fatty liver; Magnolia officinalis; Reactive oxygen species; Sterol regulatory element binding protein (SREBP); Tumor necrosis factor a (TNF a)

Indexed keywords

ALCOHOL; HONOKIOL; MAGNOLIA OFFICINALIS EXTRACT; MAGNOLOL; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; S ADENOSYLMETHIONINE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; SULFATE 4 TOLUENESULFONATE; SUPEROXIDE; TOLUENESULFONIC ACID DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALCOHOLIC FATTY LIVER; ANALYTICAL PARAMETERS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DEATH; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; EXPERIMENTAL RAT; IN VITRO STUDY; LEUKEMIA CELL; LIVER TOXICITY; MACROPHAGE; MAGNOLIA OFFICINALIS; MALE; MATURATION; MEDICINAL PLANT; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PROTEIN PROCESSING; RAT; REGULATORY MECHANISM;

EID: 66249124259     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.08182FP     Document Type: Article

References (45)

1. Li TK. Quantifying the risk for alcohol-use and alcoholattributable health disorders: present findings and future research needs. J Gastroenterol Hepatol. 2008;23 Suppl 1:S2-S8.
2. Lalor PF, Faint J, Aarbodem Y, Hubscher SG, Adams DH. The role of cytokines and chemokines in the development of steatohepatitis. Semin Liver Dis. 2007; 27:173-193.
3. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology. 1998;114:842-845.
4. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest. 2004;114:147-152.
5. Sorensen TI, Orholm M, Bentsen KD, Hoybye G, Eghoje K, Christoffersen P. Prospective evaluation of alcohol abuse and alcoholic liver injury in men as predictors of development of cirrhosis. Lancet. 1984;2:241-244.
6. Teli MR, Day CP, Burt AD, Bennett MK, James OF. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet. 1995;346:987-990.
7. You M, Matsumoto M, Pacold CM, Cho WK, Crabb DW. The role of AMP-activated protein kinase in the action of ethanol in the liver. Gastroenterology. 2004;127:1798-1808.
8. Ji C, Chan C, Kaplowitz N. Predominant role of sterol response element binding proteins (SREBP) lipogenic pathways in hepatic steatosis in the murine intragastric ethanol feeding model. J Hepatol. 2006;45:717-724.
9. Esfandiari F, You M, Villanueva JA, Wong DH, French SW, Halsted CH. S-adenosylmethionine attenuates hepatic lipid synthesis in micropigs fed ethanol with a folate-deficient diet. Alcohol Clin Exp Res. 2007;31:1231-1239.
10. Tomita K, Azuma T, Kitamura N, Nishida J, Tamiya G, Oka A, et al. Pioglitazone prevents alcohol-induced fatty liver in rats through up-regulation of c-Met. Gastroenterology. 2004;126: 873-885.
11. Wang JF, Greenberg SS, Spitzer JJ. Chronic alcohol administration stimulates nitric oxide formation in the rat liver with or without pretreatment by lipopolysaccharide. Alcohol Clin Exp Res. 1995;19:387-393.
12. Nolan JP. Endotoxin, reticuloendothelial function, and liver injury. Hepatology. 1981;1:458-465.
13. Stewart S, Jones D, Day CP. Alcoholic liver disease: new insights into mechanisms and preventative strategies. Trends Mol Med. 2001;7:408-413.
14. Stewart SF, Vidali M, Day CP, Albano E, Jones DE. Oxidative stress as a trigger for cellular immune responses in patients with alcoholic liver disease. Hepatology. 2004;39:197-203.
15. Enomoto N, Takei Y, Hirose M, Ikejima K, Miwa H, Kitamura T, et al. Thalidomide prevents alcoholic liver injury in rats through suppression of Kupffer cell sensitization and TNF-alpha production. Gastroenterology. 2002;123:291-300.
16. Yin HQ, Kim YS, Choi YJ, Kim YC, Sohn DH, Ryu SY, et al. Effects of tanshinone IIA on the hepatotoxicity and gene expression involved in alcoholic liver disease. Arch Pharm Res. 2008;31:659-665.
17. Zhao J, Chen H, Li Y. Protective effect of bicyclol on acute alcohol-induced liver injury in mice. Eur J Pharmacol. 2008; 586:322-331.
18. Kanzuo T. Traditional medicine and magnolia. In: Satyajit D, Sarker, Yuji M, editors. Magnolia: The genus magnolia. 1st ed. Boca Raton: CRC Press; 2002. p. 8.
19. Ogata M, Hoshi M, Shimotohno K, Urano S, Endo T. Antioxidant activity of Magnolol, honokiol, and related phenolic compounds. J Am Oil Chem Soc. 1997;74:557-562.
20. Lee J, Jung E, Park J, Jung K, Lee S, Hong S, et al. Antiinflammatory effects of magnolol and honokiol are mediated through inhibition of the downstream pathway of MEKK-1 in NF-kappaB activation signaling. Planta Med. 2005;71:338-343.
21. Butler J, Jayson GG, Swallow AJ. The reaction between the superoxide anion radical and cytochrome c. Biochim Biophys Acta. 1975;408:215-222.
22. Heitzer T, Wenzel U, Hink U, Krollner D, Skatchkov M, Stahl RA, et al. Increased NAD(P)H oxidase-mediated superoxide production in renovascular hypertension: evidence for an involvement of protein kinase C. Kidney Int. 1999;55:252-260.
23. Lieber CS, DeCarli LM. Liquid diet technique of ethanol administration: 1989 update. Alcohol Alcohol. 1989;24:197-211.
24. Lieber CS. Role of S-adenosyl-L-methionine in the treatment of liver diseases. J Hepatol. 1999;30:1155-1159.
25. Bligh EG, Dyer W J. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37:911-917.
26. Neuschwander-Tetri BA, Roll FJ. Glutathione measurement by high-performance liquid chromatography separation and fluorometric detection of the glutathione-orthophthalaldehyde adduct. Anal Biochem. 1989;179:236-241.
27. She QB, Nagao I, Hayakawa T, Tsuge H. A simple HPLC method for the determination of S-adenosylmethionine and Sadenosylhomocysteine in rat tissues: the effect of vitamin B6 deficiency on these concentrations in rat liver. Biochem Biophys Res Commun. 1994;205:1748-1754.
28. Yin HQ, Lee BH. Temporal changes in the hepatic fatty liver in mice receiving standard Lieber-DeCarli diet. Toxicol Res. 2008;24:113-117.
29. You M, Crabb DW. Recent advances in alcoholic liver disease II. Minireview: molecular mechanisms of alcoholic fatty liver. Am J Physiol Gastrointest Liver Physiol. 2004;287:1-6.
30. Iimuro Y, Gallucci RM, Luster MI, Kono H, Thurman RG. Antibodies to tumor necrosis factor alfa attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat. Hepatology. 1997;26:1530-1537.
31. Yin M, Wheeler MD, Kono H, Bradford BU, Gallucci RM, Luster MI, et al. Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice. Gastroenterology. 1999; 117:942-952.
32. Bykov I, Jarvelainen H, Lindros K. L-carnitine alleviates alcohol-induced liver damage in rats: role of tumour necrosis factor-alpha. Alcohol Alcoholism. 2003;38:400-406.
33. Memon RA, Grunfeld C, Moser AH, Feingold KR. Tumor necrosis factor mediates the effects of endotoxin on cholesterol and triglyceride metabolism in mice. Endocrinology. 1993;132: 2246-2253.
34. Raina N, Matsui J, Cunnane SC, Jeejeebhoy KN. Effect of tumor necrosis factor-alpha on triglyceride and phospholipid content and fatty acid composition of liver and carcass in rats. Lipids. 1995;30:713-718.
35. Kono H, Rusyn I, Yin M, Gabele E, Yamashina S, Dikalova A, et al. NADPH oxidase-derived free radicals are key oxidants in alcohol-induced liver disease. J Clin Invest. 2000;106:867-872.
36. Polavarapu R, Spitz DR, Sim JE, Follansbee MH, Oberley LW, Rahemtulla A, et al. Increased lipid peroxidation and impaired antioxidant enzyme function is associated with pathological liver injury in experimental alcoholic liver disease in rats fed diets high in corn oil and fish oil. Hepatology. 1998;27:1317-1323.
37. Pessayre D, Fromenty B. NASH: a mitochondrial disease. J Hepatol. 2005;42:928-940.
38. Fromenty B, Grimbert S, Mansouri A, Beaugrand M, Erlinger S, tig A, et al. Hepatic mitochondrial DNA deletion in alcoholics: Association with microvesicular steatosis. Gastroenterology. 1995;108:193-200.
39. Pan M, Cederbaum AI, Zhang YL, Ginsberg HN, Williams KJ, Fisher EA. Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production. J Clin Invest. 2004;113:1277-1287.
40. Yin HQ, Kim M, Kim JH, Kong G, Kang KS, Kim HL, et al. Differential gene expression and lipid metabolism in fatty liver induced by acute ethanol treatment in mice. Toxicol Appl Pharmacol. 2007;223:225-233.
41. Carrasco MP, Marco C, Segovia JL. Chronic ingestion of ethanol stimulates lipogenic response in rat hepatocytes. Life Sci. 2001;68:1295-1304.
42. Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell. 1997;89:331-340.
43. Shimano H, Shimomura I, Hammer RE, Herz J, Goldstein JL, Brown MS, et al. Elevated levels of SREBP-2 and cholesterol synthesis in livers of mice homozygous for a targeted disruption of the SREBP-1 gene. J Clin Invest. 1997;100:2115-2124.
44. Shimano H, Horton JD, Hammer RE, Shimomura I, Brown MS, Goldstein JL. Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a. J Clin Invest. 1996;98:1575-1584.
45. Yahagi N, Shimano H, Hasty AH, Matsuzaka T, Ide T, Yoshikawa T, et al. Absence of 2sterol regulatory elementbinding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice. J Biol Chem. 2002;277:19353-19357.